Episode 76
Biotech Hangout
00:00
Immunik's Positive Interimface 2 Data for MS Product
The speakers discuss the mechanism and limitations of Immunik's MS drug, as well as advancements in MS treatment options. They highlight the need for a treatment for non-active MS patients and discuss Immunik's phase two data, specifically neurofilament biomarker data.
Play episode from 43:19
Transcript
